Practical Lipid Management

Lipid management is a key part of medical practice, affecting the prevention and treatment of several diseases, including diabetes, cardiovascular disease and stroke. A practical text on the clinical management of dyslipidemias, Practical Lipid Management balances conceptual development and pathophysiology with a straightforward approach to the identification and treatment of abnormalities in lipid metabolism. The book explores the role of novel risk markers in clinical practice, summarizes the current guidelines for lipid management, and offers a critical and systematic approach to interpreting the results of clinical trials. A feature of the book is a set of sidebars which explore current controversies and unanswered questions in clinical lipidology. The treatment of specific dyslipidemias is illustrated with case studies. Treatment algorithms are also provided. Practical Lipid Management: details the relationship between specific lipids, lipoproteins and cardiovascular disease, provides guidance on the etiology and diagnosis of lipid abnormalities, summarizes current understanding of atherogenesis, and reviews the evidence base for the use of therapeutic lifestyle change and specific lipid-lowering medications to reduce morbidity and mortality from cardiovascular disease. Practical Lipid Management provides a concise summary of best practice according to various international guidelines, making it a useful tool for all primary care physicians and others involved in the management of diseases such as diabetes, cardiovascular disease and stroke. It will serve as an evidence-based, rapid, and valuable resource for family physicians, internists, nurse practitioners, physician assistants, cardiologists, endocrinologists and allied health professionals involved in the care of patients with lipid disorders.

Foreword. Preface. Acknowledgements. Chapter 1 Epidemiology of Lipids, Lipid Management and Risk for Coronary Heart Disease: An Overview. 1.1 Early History of Cardiovascular Epidemiology. 1.2 Lipid Risk Factors are Central to Efforts at CHD Prevention. 1.3 LDL-C and CHD Risk. 1.4 LDL-C Lowering and CHD Risk Reduction. 1.5 Other Atherogenic Lipoproteins: Atherogenic Remnants. 1.6 HDL-C and CHD Risk. 1.7 Trends in Lipids and Lipid Management in the USA. 1.8 The National Cholesterol Education Program Evaluation Project Using Novel E-Technology (NEPTUNE) II Survey. Controversy: Should a Measure of Atherogenic Lipoprotein Particle Number be used in Risk Assessment And/Or to Evaluate the Response to Lipid Therapy? Chapter 2 Vascular Biology and Atherogenesis. 2.1 Introduction. 2.2 Arterial Structure. 2.3 Endothelial Cell Function and Dysfunction. 2.4 The Role of Monocytes and Lymphocytes. 2.5 Atheromatous Plaques. Chapter 3 Detection, Evaluation, and Treatment Goals for Lipid Disorders in Adults. 3.1 Matching Aggressiveness of Treatment to Absolute Risk. 3.2 Screening for Dyslipidemias. 3.3 Risk Stratification. 3.4 Steps in the Risk Stratification Process – Major Risk Categories. 3.5 Tips for Calculating the Framingham Risk Score. 3.6 Subcategories for Consideration ofMore Aggressive Optional Treatment Goals. 3.7 Very High Risk Patients, Optional LDL-C Goal